Previous 10 | Next 10 |
Vaccinex (NASDAQ: VCNX ) : Q2 GAAP EPS of -$0.39 beats by $0.12 . More news on: Vaccinex, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
On track to report potentially pivotal Phase 2 Huntington’s disease topline data by early October Phase 1/2 trial of pepinemab in Alzheimer’s disease to begin enrolling patients in September Raised net proceeds of $19.8 million since June 30 ROCHESTER, N.Y., Aug. ...
Gainers: Verona Pharma (NASDAQ: VRNA ) +181% . More news on: Verona Pharma plc, RumbleON, Inc., Checkpoint Therapeutics, Inc., Stocks on the move, , Read more ...
RumbleON (NASDAQ: RMBL ) +117% on pilot program with CarGurus. More news on: RumbleON, Inc., Verona Pharma plc, Applied DNA Sciences, Inc., Stocks on the move, , Read more ...
Gainers: INmune Bio (NASDAQ: INMB ) +114% . More news on: INmune Bio, Inc., Perceptron, Inc., Rigel Pharmaceuticals, Inc., Stocks on the move, , Read more ...
Vaccinex ( VCNX +18.3% ) is up again, although 19% off the intraday high of $6.64, adding to its week-long rally after announcing that it remains on track to complete the pivotal Phase 2 SIGNAL study evaluating lead drug pepinemab in Huntington's disease patients on schedule. Shares ha...
ROCHESTER, N.Y., July 07, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Huntington’s disease (HD) and cancer, today announced that, notwithstanding the challenges posed by the ongo...
Investment Thesis Vaccinex share price performance since IPO. Source: TradingView . A review of Vaccinex's ( VCNX ) recent share price performance and funding runway might persuade investors to leave this early stage biotech stock well alone, but there is also a case to be made that the s...
Live video moderated discussion with President and CEO, Maurice Zauderer, Ph.D., on Tuesday, June 16, at 10:00 AM ET, immediately followed by an interactive Q&A session ROCHESTER, N.Y., June 09, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology ...
Vaccinex (NASDAQ: VCNX ): Q1 GAAP EPS of -$0.45 beats by $0.30 . More news on: Vaccinex, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Company expects to lock database in June and remains on track to report key outcomes later in July. Pepinemab targets astrocyte reactivity and neuroinflammation, believed to be key drivers of neurodegeneration. ROCHESTER, N.Y., June 06, 2024 (GLOBE NEWSWIRE) -- Vaccinex, I...
A look at the top 10 most actives in the United States Novo Integrated Sciences Inc. (NVOS) rose 132.8% to $1.05 on volume of 308,155,573 shares Greenwave Technology Solutions Inc. (GWAV) fell 7.9% to $0.0387 on volume of 278,348,616 shares Faraday Future Intelligent Electric Inc. (FFIE) ...
Vaccinex, Inc. (NASDAQ: VCNX) is one of today's top gainers. The company's shares have moved 15.16% on the day to $6. Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet...